How this $1.8 million drug is trying to disrupt the drug pricing system

2:58 PM ET Fri, 14 June 2019

Bluebird Bio's new drug is priced at $1.8 million. Nick Leschly, Bluebird Bio CEO, and CNBC's Meg Tirrell join 'The Exchange' to discuss Bluebird Bio's gene therapy payment program at a time when drug prices are on the rise.